CLSI EP28
Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory
This document provides guidelines for determining reference values and reference intervals for quantitative clinical laboratory tests. It is designed to help laboratories establish accurate and reliable reference ranges, which are essential for interpreting test results and ensuring high-quality patient care.
This reaffirmed document has been reviewed and confirmed as suitable to remain published without revision to content, as of April 2020.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceClinical and Laboratory Standards Institute document EP28-A3c—Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline—Third Edition is written for users of diagnostic laboratory tests. It offers a protocol for determining reference intervals that meet the minimum requirements for reliability and usefulness. The guideline focuses on health-associated reference values as they relate to quantitative clinical laboratory tests. Included are various requirements for studies to determine reference values for a new analyte or a new analytical method of a previously measured analyte. Also discussed is the transfer of established reference values from one laboratory to another.
This document provides diagnostic laboratories and diagnostic test manufacturers with updated guidelines for determining reference intervals for quantitative laboratory tests. It includes specific recommendations regarding procedures that can be used to establish and verify reliable reference intervals for use in clinical laboratory medicine. By following these recommendations, laboratories can provide reference intervals that are adequate and useful for clinical interpretation.
Issues related to the reference subject selection process, the importance of preanalytical and analytical considerations, the calculation methods and requirements for estimating valid reference intervals, and the transference of reference intervals are discussed. Examples of the recommended estimation and calculation processes are provided. Finally, issues related to the presentation and use of reference intervals are discussed, followed by a brief section that examines a number of important but collateral reference value topics not amenable to inclusion in this document.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This document is available in electronic format only.
A CLSI-IFCC joint project.
CLSI EP28IG
Free
Clinical and Laboratory Standards Institute document EP28-A3c—Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline—Third Edition is written for users of diagnostic laboratory tests. It offers a protocol for determining reference intervals that meet the minimum requirements for reliability and usefulness. The guideline focuses on health-associated reference values as they relate to quantitative clinical laboratory tests. Included are various requirements for studies to determine reference values for a new analyte or a new analytical method of a previously measured analyte. Also discussed is the transfer of established reference values from one laboratory to another.
This document provides diagnostic laboratories and diagnostic test manufacturers with updated guidelines for determining reference intervals for quantitative laboratory tests. It includes specific recommendations regarding procedures that can be used to establish and verify reliable reference intervals for use in clinical laboratory medicine. By following these recommendations, laboratories can provide reference intervals that are adequate and useful for clinical interpretation.
Issues related to the reference subject selection process, the importance of preanalytical and analytical considerations, the calculation methods and requirements for estimating valid reference intervals, and the transference of reference intervals are discussed. Examples of the recommended estimation and calculation processes are provided. Finally, issues related to the presentation and use of reference intervals are discussed, followed by a brief section that examines a number of important but collateral reference value topics not amenable to inclusion in this document.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This document is available in electronic format only.
A CLSI-IFCC joint project.